AETHLON MEDICAL, INC. (NASDAQ:AEMD) Files An 8-K Submission of Matters to a Vote of Security Holders
ITEM 5.07
We held our 2018 Annual Meeting of Shareholders on March 27, 2019. At the Annual Meeting, our stockholders approved the two proposals listed below. Based on the report of the Inspector of Elections for the Annual Meeting, 14,931,774 shares out of 18,960,505 shares outstanding and entitled to vote, or approximately 78.75%, were present at the meeting, in person or by proxy. The final results for the votes regarding each proposal are set forth in the following tables. Each of these proposals is described in detail in the proxy statement.
| 1. | Elect six members of the Board of Directors. All of the nominees were elected. |
| Name | Votes For | Abstentions |
| Edward G. Broenniman | 5,597,074 | 839,707 |
| Guy F. Cipriani | 6,044,124 | 392,657 |
| Charles J. Fisher, Jr., MD | 6,046,338 | 390,443 |
| Sabrina Martucci Johnson | 6,046,864 | 389,917 |
| T.C., Rodell, MD, FCCP | 6,044,273 | 392,508 |
| Chetan S. Shah, MD | 6,106,997 | 329,784 |
|
2. |
Ratify the appointment of Squar Milner LLP as our independent registered public accounting firm for our fiscal year ending March 31, 2019. The resolution was approved. |
| Votes For | Votes Against | Abstentions |
| 14,667,281 | 255,579 | 8,914 |
About AETHLON MEDICAL, INC. (NASDAQ:AEMD)
Aethlon Medical, Inc. is a medical device company focused on creating devices for cancer, infectious disease and other life-threatening conditions. The Company operates through two segments: Aethlon, which represents its therapeutic business activities, and ESI, which represents its diagnostic business activities. The Company’s lead product is the Aethlon Hemopurifier, which is a device that selectively targets the elimination of circulating viruses and tumor-secreted exosomes that promote cancer progression. The Aethlon Hemopurifier sheds glycoproteins to treat infectious viral pathogens. In oncology indications, the Hemopurifier targets the removal of circulating exosomes, which are released to promote cancer progression and to seed the spread of metastasis. Through its subsidiary, Exosome Sciences, Inc. (Exosome), the Company is also developing exosome-based product candidates to diagnose and monitor neurological disorders and cancer.